Continuous Medication Guide: How long to stop taking venetoclax/venetoclax

Venetoclax/Venetoclax (Venetoclax) is a drug used to treat certain types of leukemia. Its use and discontinuation need to be determined according to the doctor's advice and the specific situation. Under normal circumstances, treatment with venetoclax is usually a long-term process and requires a period of observation and evaluation before discontinuation. It is not recommended that patients discontinue venetoclax or change the dose on their own as this may adversely affect the effectiveness of treatment.

If the patient previously had untreated CLL (chronic lymphocytic leukemia) or SLL (small lymphocytic leukemia), venetoclax is usually taken in combination with obinutuzumab for 12 months. If the patient has been previously treated for CLL or SLL, venetexate is usually taken in combination with rituximab for up to 24 months. For patients with AML (acute myeloid leukemia), the once-daily maintenance dosing cycle should be continued for as long as the physician deems venetoclax safe (until disease progression or unacceptable toxicity is observed), usually in combination with another therapy.

The original drug of Venekra has been launched in China and has been included in Class B medical insurance. The price of 100mg*14 tablets per box may be around 2,000 RMB, while the Turkish version of the original drug sold overseas, with the specification of 100mg*112 tablets, costs more than 10,000 RMB per box (the price may fluctuate due to the exchange rate). There are also cheaper generic drugs of Venacla sold overseas. Their pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 100mg*120 tablets produced by a Bangladesh pharmaceutical factory is more than 4,000 yuan per box (the price may fluctuate due to the exchange rate).